Skip to main content
Open Access Publications from the University of California


UCLA Previously Published Works bannerUCLA

A novel anionic-phosphate-platinum complex effectively targets an undifferentiated pleomorphic sarcoma better than cisplatinum and doxorubicin in a patient-derived orthotopic xenograft (PDOX).

  • Author(s): Igarashi, Kentaro
  • Kawaguchi, Kei
  • Murakami, Takashi
  • Kiyuna, Tasuku
  • Miyake, Kentaro
  • Yamamoto, Norio
  • Hayashi, Katsuhiro
  • Kimura, Hiroaki
  • Nelson, Scott D
  • Dry, Sarah M
  • Li, Yunfeng
  • Singh, Arun S
  • Miwa, Shinji
  • Odani, Akira
  • Eilber, Fritz C
  • Tsuchiya, Hiroyuki
  • Hoffman, Robert M
  • et al.

A patient high-grade undifferentiated pleomorphic soft-tissue sarcoma (UPS) from a striated muscle was previously orthotopically implanted in the right biceps femoris muscle of nude mice to establish a patient-derived orthotopic xenograft (PDOX) nude-mouse model. In the present study, two weeks after orthotopic transplantation of the UPS, mice were treated intraperitoneally with cisplatinum (CDDP), doxorubicin (DOX) or a novel anionic-phosphate-platinum compound 3Pt. Treatments were repeated weekly for a total of 3 times. Six weeks after transplantation, all mice were sacrificed and evaluated. After two weeks treatment, tumor sizes were as follows: control (G1): 2208.3 mm3; CDDP (G2): 841.8±3 mm3, p=0.0001; DOX (G3): 693.1±3 mm3, p=6.56E-7; 3Pt (G4): 333.7±1 mm3, p=4.8E-8. 3Pt showed significantly more efficacy compared to other therapy drugs tested: CDDP (p=0.0002), DOX (p=0.001). There were no animal deaths in any of the four groups. The present results suggest 3Pt is a promising new candidate for UPS since it was demonstrated to be effective in a PDOX model.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
Current View